Evidence map›Paper›PMID 34075073›Full record

Trial reportScientific reports2021

Identification of CRF89_BF, a new member of an HIV-1 circulating BF intersubtype recombinant form family widely spread in South America.

Elena Delgado, Aurora Fernández-García, Marcos Pérez-Losada, María Moreno-Lorenzo, Ismael Fernández-Miranda, Sonia Benito, Vanessa Montero, Horacio Gil, Silvia Hernáez, Josefa Muñoz and 18 more

Erratum issuedOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 13 institutions in 3 countries.

Elena Delgado *HIV Biology and Variability Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Aurora Fernández-García *HIV Biology and Variability Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Marcos Pérez-LosadaDepartment of Biostatistics and Bioinformatics, Computational Biology Institute, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
María Moreno-LorenzoHIV Biology and Variability Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Ismael Fernández-MirandaHIV Biology and Variability Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Sonia BenitoHIV Biology and Variability Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Vanessa MonteroHIV Biology and Variability Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Horacio GilHIV Biology and Variability Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Silvia HernáezHospital Universitario Basurto, Bilbao, Spain.
Josefa MuñozHospital Universitario Basurto, Bilbao, Spain.
Miren Z Zubero-SulibarriaHospital Universitario Basurto, Bilbao, Spain.
Elena García-BodasHIV Biology and Variability Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Mónica SánchezHIV Biology and Variability Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Jorge Del RomeroCentro Sanitario Sandoval, Madrid, Spain.
Carmen RodríguezCentro Sanitario Sandoval, Madrid, Spain.
Luis ElorduyHospital Universitario Cruces, Instituto de Investigación Biocruces, Baracaldo, Vizcaya, Spain.
Elena BereciartuaHospital Universitario Cruces, Instituto de Investigación Biocruces, Baracaldo, Vizcaya, Spain.
Esther CulebrasHospital Clínico Universitario San Carlos, Madrid, Spain.
Icíar Rodríguez-AvialHospital Clínico Universitario San Carlos, Madrid, Spain.
María Luisa Giménez-AlarcónHospital Virgen de La Luz, Cuenca, Spain.
Carmen Martín-SalasComplejo Hospitalario de Navarra, Pamplona, Spain.
Carmen Gómez-GonzálezHospital Universitario Araba, Vitoria-Gasteiz, Spain.
José J García-IrureHospital Reina Sofía, Tudela, Navarra, Spain.
Gema CenzualHospital Universitario Severo Ochoa, Leganés, Madrid, Spain.
Ana Martínez-SapiñaHospital Universitario Miguel Servet, Zaragoza, Spain.
María Maiques-CamareroHospital Nuestra Señora del Prado, Talavera de la Reina, Toledo, Spain.
Lucía Pérez-ÁlvarezHIV Biology and Variability Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Michael M ThomsonHIV Biology and Variability Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. mthomson@isciii.es.
Centro Nacional de Microbiologia · ESInstituto de Salud Carlos III · ESHospital de Basurto · ESBioCruces Health research Institute · ESHospital Clínico San Carlos · ESComplejo Hospitalario de Navarra · ESGeorge Washington University · USHospital General Nuestra Señora del Prado · ESHospital Universitario Araba · ESHospital Universitario Miguel Servet · ESHospital Universitario Reina Sofía · ESHospital Universitario Severo Ochoa · ESHospital Virgen de la Luz · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating recombinant forms (CRFs) contribute substantially to the HIV-1 pandemic. Among 105 CRFs described in the literature, 16 are BF intersubtype recombinants, most of South American origin, of which CRF12_BF is the most widely spread. A BF recombinant cluster identified in Bolivia was suggested to represent a new CRF_BF. Here we find that it belongs to a larger cluster incorporating 39 viruses collected in 7 countries from 3 continents, 22 of them in Spain, most from Bolivian or Peruvian individuals, and 12 in South America (Bolivia, Argentina, and Peru). This BF cluster comprises three major subclusters, two associated with Bolivian and one with Peruvian individuals. Near full-length genome sequence analyses of nine viruses, collected in Spain, Bolivia, and Peru, revealed coincident BF mosaic structures, with 13 breakpoints, 6 and 7 of which coincided with CRF12_BF and CRF17_BF, respectively. In a phylogenetic tree, they grouped in a clade closely related to these CRFs, and more distantly to CRF38_BF and CRF44_BF, all circulating in South America. These results allowed to identify a new HIV-1 CRF, designated CRF89_BF. Through phylodynamic analyses, CRF89_BF emergence was estimated in Bolivia around 1986. CRF89_BF is the fifth CRF member of the HIV-1 recombinant family related to CRF12_BF.

Indexed as

Genetic VariationGenome, ViralPhylogenyRecombination, GeneticAdultFemaleHIV-1HIV InfectionsHumansMaleMiddle AgedSequence Analysis, DNASouth America

Identifiers

PMID34075073
PMCPMC8169922
OpenAlexW3132705982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.